Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

This extended follow-up analysis further supports SHR2554 as a therapeutic opportunity for patients with r/r PTCL.

Keyphrases